Danish pharmaceutical company Novo Nordisk announced its collaboration with OpenAI, the parent company of ChatGPT, to accelerate drug development through artificial intelligence. According to reports from CNBC, the partnership aims to bring 'new and better treatment options to patients faster' by enabling the drugmaker to better analyze complex datasets and identify promising new drugs. The collaboration will launch pilot programmes across research and development, manufacturing and commercial operations, with full integration by the end of 2026. As reported by OpenAI, the partnership extends beyond traditional drug development to include upskilling the company's global workforce and enhancing AI literacy. Through this expanded scope, OpenAI's capabilities will also be used to improve efficiency in manufacturing, supply chain and distribution, and corporate operations. This deal comes as the total value of AI partnerships takes a 120% uptick year-on-year between 2024 and 2025, as per GlobalData.
Novo Nordisk CEO Mike Doustdar emphasized the transformative potential of AI integration, stating that there are millions of people living with obesity and diabetes who need treatment options. As reported by The Wall Street Journal, Doustdar highlighted that integrating AI in everyday work provides the ability to analyze datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever. OpenAI CEO Sam Altman responded by noting that 'AI is reshaping industries and in life sciences, it can help people live better, longer lives'. According to OpenAI, this partnership is positioned as 'one important step in positioning Novo Nordisk to lead in the next era of healthcare'. The collaboration is part of a broader trend, with Novo Nordisk joining pharma companies like Sanofi, Moderna, Thermo Fisher Scientific and Eli Lilly in forging alliances with the tech giant.
The company has deployed NovoScribe, an AI-powered platform built using MongoDB Atlas Vector Search, Amazon Bedrock and LangChain to automate and accelerate the creation of clinical study reports. As reported by Novo Nordisk, NovoScribe reduces the time to regulatory submissions. The company has also established a data pool called FounData, where all data from completed clinical trials are pooled and prepared for insights-generation. In 2024, Novo Nordisk presented its strategy during its Capitals Market Day, showing it set up an AI centre of excellence in 2021 and had begun ramping up investment in high performance computing and graphics processor units by 2023. The company's AI strategy includes strict data protection, governance and human oversight to ensure ethical and compliant use.
The partnership announcement drove positive market reaction, with Novo Nordisk stock jumping 2.8% shortly after opening bell. According to CNBC, drug companies are increasingly relying on advanced modelling tools and automated labs to enhance research and development pipelines. While artificial intelligence could discover new treatments, experts suggest that the industry is far from fully realizing its capabilities, with more practical benefits expected from applying AI to streamlining patient recruitment and clinical trial processes. The partnership builds on Novo Nordisk's existing technology collaborations with AWS, Microsoft, Google and Hugging Face, demonstrating the company's commitment to leveraging advanced technology across its entire drug development pipeline. Meanwhile, AI is also taking the fancy of life science investors, with GlobalData's Pharmaceutical Intelligence Center revealing that the total value of venture financing deals saw a 48% uptick in 2025 compared with the previous year.
The partnership comes as Novo Nordisk competes closely with US rival Eli Lilly for leadership in the highly profitable weight-loss market. As reported by Live Mint, the Danish drugmaker is working to regain market share with its Wegovy pill launched in January, as well as developing next-generation treatments. In March, Eli Lilly secured a $2.75 billion deal with Insilico Medicine to introduce AI-developed drugs in the global market, with Insilico Medicine receiving $115 million upfront plus additional payments tied to regulatory approvals and commercial milestones. According to GlobalData's Pharmaceutical Intelligence Center, Lilly has signed 16 AI-based deals since 2025, with notable examples being its $1bn partnership with NVIDIA. While Lilly may pose a challenge to Novo's initial obesity market reign, the partnership positions Novo Nordisk to compete more effectively in the AI-driven drug discovery landscape.
